The global pertussis initiative: Meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010 - Commentary

Human Vaccines

Volumn 7, Issue 4, 2011, Pages

  Guiso, Nicole ^a   Liese, Johannes ^b   Plotkin, Stanley ^c  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Africa; Central and Eastern Europe; Incidence; Middle East; Pertussis; Vaccination

Indexed keywords

IMMUNOGLOBULIN G; PERTUSSIS VACCINE;

AFRICA; BORDETELLA PERTUSSIS; DISEASE SURVEILLANCE; DRUG DOSE REGIMEN; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FRANCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PLANNING; HEALTH PROMOTION; HUMAN; IMMUNIZATION; INCIDENCE; MIDDLE EAST; NOTE; PERTUSSIS; REAL TIME POLYMERASE CHAIN REACTION; VACCINATION;

EID: 79955031209     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.4.14528     Document Type: Note

References (23)

1. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802-9. (Pubitemid 39657260)
2. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634-42. (Pubitemid 46400927)
3. Forsyth K, Nagai M, Lepetic A, Trindade E. Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24:93-7.
4. Wirsing von Konig CH, Campins-Marti M, Finn A, Guiso N, Mertsola J, Liese J. Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24:87-92.
5. Tan T, Halperin S, Cherry JD, Edwards K, Englund JA, Glezen P, et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24:83-6.
6. WHO-recommended surveillance standard of pertussis. Accessed November 16, 2010; http://www.who.int/immunization-monitoring/diseases/pertussis- surveillance/en/index.html.
7. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-87.
8. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24:10-8.
9. Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005; 24:19-24.
10. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24:58-61.
11. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3:93-7. (Pubitemid 26040690)
12. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161:142-6. (Pubitemid 34169862)
13. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21:2024-30. (Pubitemid 36428792)
14. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:81.
15. Guiso N, Njamkepo E, Vie le Sage F, Zepp F, Meyer CU, Abitbol V, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390-7.
16. Riffelmann M, Wirsing von Konig CH, Caro V, Guiso N. Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol 2005; 43:4925-9. (Pubitemid 41483986)
17. Riffelmann M, Thiel K, Schmetz J, von Konig CH. Performance of commercial enzyme-linked immunosorbent assays for the detection of antibodies to Bordetella pertussis. J Clin Microbiol 2010; 48:4459-63
18. Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, von Konig CH. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011; 30:307-12
19. Kurova N, Njamkepo E, Brun D, Tseneva G, Guiso N. Monitoring of Bordetella isolates circulating in Saint Petersburg, Russia between 2001 and 2009. Res Microbiol 2010; 161:810-5
20. Zouari A, Smaoui H, Njamkepo E, Mnif K, Ben Jaballah N, Bousnina S, et al. [The re-emergence of pertussis in Tunisia]. Med Mal Infect 2011; 41:91-101
21. Grgic-Vitek M, Klavs I, Kraigher A. Re-emergence of pertussis in Slovenia: time to change immunization policy. Vaccine 2008; 26:1874-8.
22. Petrovic V, Duric P, Stefanovic S. [Epidemiological characteristics of pertussis in Vojvodina]. Med Pregl 2006; 59:19-23.
23. Whooping cough in Tunisia: the resurrection. Presented at: European Society for Paediatric Infectious Diseases (ESPID), 4-8 May 2010. Poster P224. Accessed October 13, 2010; http://www.kenes.com/espid2010/posters/Abstract149. htm.